Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketwatch.com)